Pricing Log in Create free account

Fate Therapeutics, Inc. (FATE) vs Keros Therapeutics, Inc. (KROS)

Fate Therapeutics, Inc. and Keros Therapeutics, Inc. are both Biotechnology companies. Fate Therapeutics, Inc. and Keros Therapeutics, Inc. are of similar size ($230.7M and $220.1M). Fate Therapeutics, Inc. grew revenue faster over the last twelve months: −23.4% against −84.6%. Keros Therapeutics, Inc. has the higher net margin (0.00% vs −1,941.1%) and the lower return on invested capital (−1,345.3% vs 0.00%). Across the 16 metrics below, Keros Therapeutics, Inc. leads on 14 and Fate Therapeutics, Inc. on 2.

Valuation

Metric FATE KROS Biotechnology median
P/E n/m n/m 8.50
P/S 33.20 6.37 9.71
P/B 1.40 0.81 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.46 0.64
EV/Sales 13.12 (1.39) 9.21
Earnings yield (58.66%) (34.64%) (33.15%)
Free cash flow yield (48.92%) (22.93%) (25.50%)

Profitability

Metric FATE KROS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (2,058.08%) 0.00% 0.00%
Net margin (1,941.09%) 0.00% 0.00%
Free cash flow margin (1,624.06%) 0.00% 0.00%
Return on equity (60.75%) (17.16%) (56.36%)
Return on assets (39.89%) (15.92%) (48.04%)
Return on invested capital 0.00% (1,345.30%) 0.00%

Growth

Metric FATE KROS Biotechnology median
Revenue growth (TTM) (23.36%) (84.55%) 6.02%
EPS growth (last fiscal year) 29.88% 146.00% 30.26%
Revenue growth, 5-year CAGR (26.71%) 89.45% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FATE KROS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.85 21.96 4.72
Net debt to EBITDA 1.47 (4.16) 0.96

Dividend

Metric FATE KROS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric FATE KROS Biotechnology median
Market cap 230.65m 220.08m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack